2026 ACA 156th Congress of Correction Pittsburgh_Program Book

SATURDAY, AUG. 1

11 A.M.–12 P.M.

• Examine the use of continuous glucose monitors (CGMs) in correctional healthcare, including clinical benefits, implementation strategies, cost considerations, and security-related challenges. • Evaluate the role of insulin pump therapy in correctional settings, including patient selection, clinical outcomes, operational considerations, and potential risks and barriers to use. Moderator: Randolph Maul , Chief Medical Officer, Colorado Department of Corrections, Colorado Springs, Colorado Speaker: Stephanie Gravning , Chief Medical Officer, North Dakota Department of Corrections and Rehabilitation, Bismarck, North Dakota Rethinking Suicide Risk Assessment in Corrections: From Prediction and Restriction to Risk Formulation and Tailored Interventions [CME|CEU|CERP] Room: 320 Primary Community of Focus: Behavioral Health Overview: Traditional suicide prevention in correctional facilities often relies on the construct of risk prediction—a method increasingly challenged by research and international associations (NICE, 2022). Drawing on Craig Bryan’s (2022) framework of suicide as a “wicked problem,” this workshop explores how focusing on prediction can lead us away from seeing the full picture. This session will introduce a risk formulation approach that aligns with the existing correctional practices, scientific research, and links individualized interventions with system efforts for prevention. Learning Objectives: • Define the prediction paradox and the impact low base rates have on prediction. • Describe an approach to suicide and self-injury risk assessment that includes a therapeutic and tailored risk formulation. • Identify collaborative treatment planning and interventions that integrate existing

Clinical Updates: GLP-1s, Continuous Glucose Monitors, and Insulin Pumps [CME|CEU|CERP] Room: 321 Primary Community of Focus: Adult Corrections Overview: Diabetes is a prevalent and increasingly complex chronic condition in correctional populations, requiring consistent access to medications, monitoring tools, and individualized management strategies. Community standards emphasize the importance of timely access to insulin, glucose monitoring, and advanced diabetes technologies to prevent complications and improve outcomes; however, correctional settings present unique operational, security, and resource-related challenges that can limit implementation. Despite advances in diabetes care, including GLP-1 receptor agonists, continuous glucose monitors (CGMs), and insulin pump technologies, there remains a gap in correctional healthcare related to clinician knowledge, implementation strategies, and balancing clinical benefits with operational and security constraints. This gap contributes to variability in adoption of evidence-based practices and may impact glycemic control, patient safety, and long-term outcomes. This session will address these challenges by examining the clinical utility, implementation considerations, and barriers associated with GLP-1 medications, CGMs, and insulin pumps in correctional settings, with the goal of supporting informed, evidence-based decision-making to optimize diabetes management. Learning Objectives: • Analyze the mechanisms of action, current clinical uses, and potential applications of GLP-1 receptor agonists in correctional settings, including considerations for cost, outcomes, and alignment with standards of care.

WORKSHOPS Saturday, Aug. 1 ▼ 8 a.m.–5 p.m.

142 — ACA 156 th Congress of Correction | Pittsburgh